Printer Friendly

MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION

 MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND
 SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
 PHILADELPHIA, June 16 /PRNewswire/ -- The state of Michigan Department of Public Health and SmithKline Beecham (NYSE: SHB) (SB) today announced the signing of a letter of intent to cooperate in the distribution and joint development of pediatric vaccines.
 Under the agreement, SmithKline Beecham will be the exclusive U.S. distributor outside the state of Michigan of certain vaccines developed by the Michigan Department of Public Health (MDPH) and currently distributed by MDPH to health clinics in Michigan. The vaccines are against: diphtheria, tetanus, whole-cell pertussis and rabies.
 In addition, MDPH and SmithKline Beecham will jointly research and develop a series of combination pediatric vaccines for distribution in the United States. Michigan Gov. John Engler said, "Prevention of the major infectious diseases of childhood is a top priority for the state of Michigan." He stated also, "The opportunity for the state to cooperate in the provision and development of exciting new vaccines with SmithKline Beecham is testimony to the fact that government and the private sector do, indeed, have a bond of commonality."
 "This landmark collaboration dramatically hastens the progress of our strategy to develop important vaccines that protect the very young from life-threatening diseases," said Dr. JP Garnier, president of SmithKline Beecham's pharmaceuticals business in North America. "We hope it serves as a blueprint for future collaboration between government and industry."
 SmithKline Beecham discovers, develops, manufactures and markets human and animal pharmaceuticals, biologicals, over-the-counter medicines, health-related consumer brands and clinical laboratory testing services. The company's flagship vaccine is Engerix-B, the world's leading genetically engineered human vaccine for the prevention of hepatitis B infection. SmithKline Beecham is the world's largest supplier of polio vaccine and recently introduced the world's first hepatitis A vaccine in Europe.
 /delval/
 -0- 6/16/91
 /CONTACT: Jeremy Heymsfeld, 215-751-5166, or Richard Williams (financial), 215-751-7002, both of SmithKline Beecham/
 (SBH) CO: SmithKline Beecham; Michigan Department of Public Health ST: Pennsylvania, Michigan IN: MTC SU:


CC -- PH005 -- 0525 06/16/92 09:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 16, 1992
Words:337
Previous Article:FAA AWARDS CONTRACTS FOR ADVANCED MICROWAVE LANDING SYSTEM
Next Article:PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT
Topics:


Related Articles
PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
RIBI IMMUNOCHEM EXPANDS COMMERCIAL RELATIONSHIP WITH SMITHKLINE BEECHAM BY PROVIDING ADJUVANTS FOR IMPORTANT GROUP OF BACTERIAL VACCINES
SMITHKLINE BEECHAM TO INTRODUCE HAVRIX, HEPATITIS A VACCINE, IN THE PEOPLE'S REPUBLIC OF CHINA
TULANE UNIVERSITY AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
U.S. OUTBREAK COMMUNITIES IN NEED CAN ACCESS VACCINE THROUGH FEDERAL FUNDS
SMITHKLINE BEECHAM ENTERS RESEARCH COLLABORATIONS IN CHINA; NEXT STEP IN EXPANDING PRESENCE IN CHINESE HEALTHCARE
Flamel Technologies S.A. and SmithKline Beecham To Terminate Collaboration in Vaccine Delivery
SmithKline Beecham Announces New Drug Discovery Collaborations
SmithKline Beecham and LEO Pharmaceutical Products Enter Collaboration in Dermatology

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters